Prognosis of completely resected pn2 non–small cell lung carcinomas: What is the significant node that affects survival?  by Okada, Morihito et al.
270
N2 disease may be due to differences in the extent and
level of metastatic nodes. The station of mediastinal
lymph node metastases has not been considered as a prog-
nostic indicator for survival in most publications. Naruke
and colleagues3 reported that the prognosis of patients
with subcarinal lymph node metastases was lower than
that of patients with metastases to lymph nodes in other
mediastinal locations after surgical resection, which was
not confirmed by Martini and colleagues.4 Thus a few
studies have evaluated the effect of metastatic spread on
the survival of patients with lung cancer, but the results
have been controversial and confusing.
We reviewed the clinical records of patients with
non–small cell lung cancer, all of whom had been sub-
jected to complete resection of tumors with complete
mediastinal dissection. The purposes of this study were
to analyze the relationship among the station of medi-
astinal metastases, to analyze the location of the prima-
ry tumor and the overall survival rate, and to understand
significant nodes that affect postoperative survival. 
A lthough resection for non–small cell lung cancerremains the management of choice whenever possi-
ble, considerable controversy still exists on interpretation
of the prognostic and therapeutic implications of metas-
tases to ipsilateral mediastinal node (N2) disease. Many
physicians believe in their inability to control N2 disease
by surgical treatment and regard it as a contraindication
to thoracotomy, but some of these lesions demonstrate
relatively fine prognosis after complete resection.1,2
Varying survival associated with the surgical treatment of
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Patients and methods 
Between January 1986 and December 1996, 956 consecu-
tive patients underwent operation for primary lung cancer by
the same surgical team. Of these, 760 patients (79.5%) with
proven non–small cell carcinoma underwent curative opera-
tion, which was defined as complete removal of ipsilateral
hilar and mediastinal lymph nodes together with the primary
tumor. There were 568 men and 192 women with a mean age
of 63 years (range, 30-88 years). Patients who had evidence
of residual tumor at the surgical margin, malignant effusion,
or N3 disease (verified by intraoperative findings or postop-
erative pathologic examination) were defined as noncurative
operation and were excluded from this study. Tumors with
minute satellite nodules that were found incidentally within
the same lobe of the resected specimen were not excluded
from this study because we were not certain whether these
lesions should be considered local tumor spread or not.
Tumors with satellite lesions in another lobe were excluded.
Resected specimens were examined histopathologically, and
histologic typing was done according to the World Health
Organization classification.5 Patients whose tumors were sub-
sequently classified as small cell carcinoma or low-grade
malignant tumor were also excluded. Surgical-pathologic
staging was assigned according to the New International
Staging System for Lung Cancer.6 The lymph node classifi-
cation schema that has been recommended by the American
Joint Committee on Cancer and adapted from Naruke and
colleagues3 was used to designate N disease. 
Routine systematic dissection of all the hilar and mediasti-
nal nodes was performed in every case, even if the preopera-
tive evaluation was N0 or N1. Every node dissected en bloc
(not sampled) was placed into the compartments, with each
lymph node level numbered separately during the operation,
and was examined by pathologists to be diagnosed as micro-
scopically positive or negative after the operation. The sites of
N2 lymph nodes were divided into upper mediastinal (high-
est mediastinal nodes, paratracheal nodes, pretracheal nodes,
anterior mediastinal nodes, posterior mediastinal nodes, and
tracheobronchial angle nodes), aortic (Botallo’s nodes, para-
aortic nodes, and ascending aortic nodes), and lower medi-
astinal (subcarinal nodes, paraesophageal nodes, and pul-
monary ligament nodes) lymph nodes.3,4 Operative mortality
rates implied a 30-day postoperative mortality plus intraoper-
ative mortality. Survival was estimated by the Kaplan-Meier
method,7 and differences in survival were determined by log-
rank analysis. A multivariate analysis of various independent
prognostic factors was assessed by Cox’s proportional haz-
ards regression model.8 Zero time was the date of pulmonary
resection, and the terminal event was death attributable to
cancer, noncancer, or unknown cause. Operative death was
included.
Results 
Overall follow-up ranged from 18 to 150 months,
with a median of 61 months. The operative mortality
rate was 0.3% (2/760 patients). One patient died of
hemorrhage during completion pneumonectomy. The
cause of death in the remaining patient was acute
myocardial infarction. The relationship between the
location of the primary tumor and the pathologic N fac-
tor is shown in Table I. The status of lymph node
involvement was N0 in 480 of the 760 patients
(63.2%), N1 in 139 patients (18.3%), and N2 in 141
patients (18.5%). A significant difference in survival
according to the absence or presence of N1 or N2
nodes is shown in Fig 1. The 5-year survival of patients
with N0, N1, and N2 disease was 77%, 58%, and 26%,
respectively (N0 vs N1, P = .0009; N1 vs N2, P =
Table I. Relationship between the location of primary
tumor and pathologic N factor
Location of tumor (n)
N factor Rt-U Rt-M Rt-L Lt-U Lt-L Total (n)
pN0 135 38 92 126 89 480
pN1 38 29 18 29 25 139
pN2 48 16 22 30 25 141
Total 221 83 132 185 139 760
Rt-U, Right upper lobe; Rt-M, right middle lobe; Rt-L, right lower lobe; Lt-U,
left upper lobe; Lt-L, left lower lobe.
Fig 1. Cumulative survival curves of patients who underwent
complete resection for non–small cell lung cancer according
to surgical-pathologic status of ipsilateral mediastinal lymph
nodes. Patients with N0 disease had a significantly better sur-
vival than those patients with N1 disease (P = .0009), and
patients with N1 disease had a significantly better survival
than those patients with N2 disease (P = .0001).
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.0001). In addition, 70% of patients with N0 disease,
52% of patients with N1 disease, and 17% of patients
with N2 disease were expected to survive 10 years or
more after operation. 
In the 141 patients with N2 disease, the histologic
cell types were 98 adenocarcinoma, 40 squamous cell
carcinoma, 2 adenosquamous carcinoma, and 1 large
cell carcinoma. Histologic classification was not a sig-
nificant survival determinant (adenocarcinoma versus
squamous cell carcinoma, P = .76). Lobectomy was by
far the most common procedure and was performed in
123 patients, including 21 combined sleeve resections
of the bronchus. Fourteen pneumonectomies including
2 sleeve techniques for the tracheobronchus and 4 seg-
mentectomies were performed. Because we followed
the policy that lung-saving procedures such as bron-
choplasty must always be kept in mind,9 we performed
very few pneumonectomy procedures. The extent of
procedure did not significantly affect survival (lobecto-
my versus pneumonectomy, P = .98).
The locations and levels of involved nodes affected
survival. Patients having involvement of subcarinal
nodes from either right or left upper-lobe tumors (n = 8)
were not expected to survive 3 years after operation and
had a significantly worse prognosis than those patients
with metastases only to the upper mediastinal or aortic
nodes (n = 70; P = .003). The 5-year survival for these
patients was 0% and 37%, respectively (Fig 2). Table II
shows a multivariate analysis of independent prognostic
factors among patients with an upper-lobe tumor.
Involvement of subcarinal nodes was a statistically sig-
nificant factor (P = .023). On the other hand, patients
with nodal involvement of the upper mediastinum from
either right or left lower-lobe tumors (n = 28) had a sig-
nificantly worse survival than those with metastases
limited to the lower mediastinum (n = 19; P = .039).
The survival in these patients was 8% and 49% at 5
years, respectively (Fig 3). As a result of a multivariate
Fig 2. Cumulative survival curves of patients with an upper-
lobe tumor according to the absence or presence of subcari-
nal node metastases. Patients having involvement of subcari-
nal nodes had a significantly worse prognosis than those
patients with metastasis only to the upper mediastinal or aor-
tic nodes (P = .003).
Fig 3. Cumulative survival curves of patients with a lower-
lobe tumor according to the absence or presence of upper
mediastinal metastases. Patients with nodal involvement of
the upper mediastinum had a significantly worse survival
than those patients with metastasis only to the lower medi-
astinum (P = .039).
Fig 4. Cumulative survival curves of patients with a left
upper-lobe tumor according to the absence or presence of
aortic node metastases. Patients with involvement of only the
aortic nodes had a significantly better survival than those
patients with metastasis to the upper or lower mediastinum
over the aortic region (P = .044).
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analysis among patients with a lower-lobe tumor (Table
III), involvement of upper mediastinal nodes was iden-
tified to be an independent prognostic factor (P = .044).
Furthermore, patients with involvement of the aortic
nodes alone from left upper-lobe tumors (n = 12) had a
significantly better survival than those patients with
metastasis to the upper or lower mediastinum beyond
the aortic region (n = 18; P = .044). The 5-year survival
for these patients was 57% and 36%, respectively (Fig
4). According to a multivariate analysis among patients
with a left upper-lobe tumor (Table IV), involvement of
upper or lower mediastinal nodes over aortic nodes was
an independent prognostic factor (P = .046). We also
evaluated the effect of the number of stations of
involved N2 lymph nodes on patients’ survival. Patients
with involvement of the single station (n = 84) had a sig-
nificantly better survival than those patients with
involvement of the multiple stations (n = 57; P = .0001).
The 5-year survival for these patients was 39% and
11%, respectively. 
Discussion 
The presence of mediastinal lymph node metastases
in patients with lung cancer is a significant prognostic
factor and may profoundly influence therapeutic deci-
sions. The actuarial 5-year survival of patients with N2
non–small cell lung cancer having complete resection
reported in the literature vary between 19.2% and
Table II. Multivariable analysis of prognostic factors among patients with an upper-lobe tumor (n = 78)
Characteristics
Factors Unfavorable Favorable Risk ratio 95% CI P value
Sex Male Female 1.570 0.701-3.514 .27
Age (y) <70 70≤ 1.586 0.665-3.785 .30
Side of tumor Right Left 1.154 0.604-2.205 .66
Histologic type AD SQ 2.276 0.951-5.451 .064
Extent of involved nodes Subcarinal* Upper or aortic† 2.840 1.158-6.966 .023
CI, Confidence interval; AD, adenocarcinoma; SQ, squamous cell carcinoma.
*Involvement of subcarinal nodes.
†Involvement of only upper mediastinal or aortic nodes.
Table III. Multivariable analysis of prognostic factors among patients with a lower-lobe tumor (n = 47)
Characteristics
Factors Unfavorable Favorable Risk ratio 95% CI P value
Sex Female Male 1.191 0.495-2.864 .70
Age (y) 70≤ <70 1.084 0.481-2.440 .85
Side of tumor Left Right 1.492 0.690-3.230 .31
Histologic type SQ AD 2.053 0.807-5.221 .13
Extent of involved nodes Upper* Lower† 2.358 1.022-5.439 .044
CI, Confidence interval; AD, adenocarcinoma; SQ, squamous cell carcinoma.
*Involvement of upper mediastinal nodes.
†Involvement of only lower mediastinal nodes.
Table IV. Multivariable analysis of prognostic factors among patients with a left upper-lobe tumor (n = 30)
Characteristics
Factors Unfavorable Favorable Risk ratio 95% CI P value
Sex Male Female 2.409 0.595-9.752 .22
Age (y) 70≤ <70 1.481 0.082-26.693 .79
Histologic type AD SQ 4.858 0.268-88.052 .28
Extent of involved nodes Upper or lower* Aortic† 3.923 1.022-15.061 .046
CI, Confidence interval; AD, adenocarcinoma; SQ, squamous cell carcinoma.
*Involvement of upper or lower mediastinal nodes.
†Involvement of only aortic nodes.
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30%.10-13 However, selection of patients and methods
for reporting survival figures vary widely, thereby mak-
ing comparisons between reported series difficult, if
not impossible. It must be kept in mind that this series
included both macroscopically apparent N2 disease
and microscopic N2 disease but excluded incomplete
resection. The study was retrospective analysis, but the
number of missing data was too small; follow-up was
obtained in all patients. Because we always keep lung-
saving procedures in mind,8 pneumonectomy was per-
formed infrequently and much less than sleeve lobecto-
my. In consequence, we had fewer postoperative
complications such as pneumonia, pulmonary infarc-
tion, or pulmonary edema; and curative resection could
be done with low operative mortality rates. Because we
always perform routine systematic dissection of all the
hilar and mediastinal nodes, we have many patients
who were sliding from advanced N1 disease to early
N2 disease at postoperative pathologic examination;
that is, they had no macroscopically apparent N2 dis-
ease but microscopic N2 disease, and we had more
patients with single station of involved N2 nodes than
those with multiple stations of involved N2 nodes. In
our series, therefore, N2 disease could be considered to
achieve relatively good survival.
There have been some reports that have shown that
patients with involvement of multiple N2 stations have
a worse prognosis than those patients with involvement
of only a single N2 station.13,14 These reports were
compatible with our present study. However, the station
of mediastinal lymph node metastases in relation to the
location of the primary tumor has not been considered
a prognostic indicator for survival in most publications.
Also, the results on the importance of the involved sta-
tion are conflicting in the literature. A few reports11,15
found that the level of the nodal station involved had
only a minor effect on the potential for long-term sur-
vival and that the survival differences between the var-
ious levels of involvement appeared not to be of statis-
tical significance. Riquet and colleagues16 reported that
the distribution of the metastatic mediastinal lymph
nodes was not important for the prognosis. 
Miller and colleagues14 revealed that the survival in
patients with involvement of upper mediastinum was
improved compared with those patients with involve-
ment of the lower mediastinum, regardless of the loca-
tion of the primary tumor. Kirsh and Sloan17 reported
better survival for patients with metastases in the upper
mediastinum alone. This result was in agreement with
ours in case of upper-lobe tumors. 
Naruke and colleagues3 reported the survival of
patients with subcarinal node involvement to be 9.1%,
as opposed to a 29% 5-year survival for patients with
N2 disease without involvement of the node. In addi-
tion, Patterson and colleagues1 and Kirsh and Sloan17
reported a poor survival in patients with subcarinal
involvement. We speculated that subcarinal nodes were
significant as a cross-road where lymphatic channels
from the various organs in the thorax meet directly or
by means of lymphoid relays.18 Our own studies would
confirm the importance of the subcarinal nodes and the
poor prognostic implications when they are involved
by upper-lobe cancer. This may have been because
nodal involvement of subcarina tends to be more wide-
ly scattered. Nohl19 stated that, in upper-lobe cancers,
subcarinal lymph node metastases usually occurred
secondary to involvement of nodes around the main
bronchus and noted that subcarinal involvement was
infrequent. From these results, involvement of subcari-
nal lymph nodes from upper-lobe cancer is considered
as more advanced disease. 
Patterson and colleagues1 reported that patients with
metastasis to subaortic lymph nodes alone had a com-
paratively good prognosis after complete resection and
a 5-year survival of 42%. Martini and Flehinger11
demonstrated a 35% 5-year survival rate in patients
with similar nodal involvement. In the present study,
patients with involvement of only the aortic nodes from
left upper-lobe tumors had a significantly better sur-
vival than those patients with metastasis to the upper or
lower mediastinum. The subaortic nodes constitute an
important pathway of lymph drainage for left upper
lobe and may be equivalent to the hilar lymph nodes,
unlike the other mediastinal lymph nodes. In contrast,
Miller and colleagues14 found no difference in 5-year
survival between patients with positive disease and
negative disease in aortic nodes. 
We regarded the location of the primary tumor, which
was not under consideration in most of the past litera-
ture, very important in analyzing the relationship
between the level of involved nodes and the prognosis. 
Vansteenkiste and colleagues20 found that right upper-
and middle-lobe tumors had pathways of lymphatic
metastases to the right upper-mediastinal nodes, right
lower-lobe tumors to the lower ones, and left upper-lobe
tumors to the aortic ones. These findings were compat-
ible with our preceding study.18 A usual pattern of lym-
phatic spread not following the findings mentioned ear-
lier was considered a poor prognostic sign (eg, there
were no 3-year survivors in patients with metastases to
subcarinal nodes from an upper-lobe tumor). 
From the results of the present study, it appears that
the relationship between the station of mediastinal
lymph node metastases and the location of the primary
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tumor is important when planning therapy for patients
with N2 non–small cell lung cancer. When metastasis
limited to upper mediastinal or aortic nodes from
upper-lobe tumor, to lower mediastinal nodes from
lower-lobe tumor, or to aortic nodes from left upper-
lobe tumor, the patient should undergo as complete a
resection as possible because acceptable survival can
be expected after radical resection. 
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